Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and Neck Cancers: 2022 Multidisciplinary Head and Neck Cancers Symposium

March 31, 2022
Brielle Gregory Collins, ASCO staff

The 2022 Multidisciplinary Head and Neck Cancers Symposium was held from February 24 to 26 in Phoenix, Arizona.

In this podcast, Kedar Kirtane, MD, discusses the research presented at the meeting, including discussions around cancer disparities in head and neck cancer, treatment for HPV-positive oropharyngeal cancer, and strategies for treating HPV-related head and neck cancers.

  • An overview of discussions from doctors based in Alabama and Georgia on cancer disparities in Black people with head and neck cancer and the importance of diverse representation in head and neck cancer clinical trials. [2:18]

  • Findings from a study that measured the human papillomavirus (HPV) DNA in the blood of people with HPV-positive oropharyngeal cancer treated with radiation therapy to see whether clearing the virus was associated with treatment effectiveness. [4:11]

  • An overview of a discussion about potential de-escalation strategies for treatment plans in people with HPV-related head and neck cancers, such as lowering the radiation dose or choosing a type of chemotherapy to reduce side effects while still keeping high effectiveness. [7:21]

Dr. Kirtane is an assistant member and medical oncologist at Moffitt Cancer Center in Tampa, Florida, with a focused interest in the treatment of head, neck, and endocrine malignancies. Dr. Kirtane is also the 2022 Cancer.Net Specialty Editor for Head and Neck Cancers.

Disclosure information for Dr. Kirtane can be found in his biography linked to above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content. 


Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.